We designed a multimeric nuclease-resistant 63-bp trimeric small-interfering RNA (tsiRNA) comprising in one duplex the sequence of siRNAs targeting mRNAs of MDR1, LMP2, and LMP7 genes. We show that such tsiRNA is able to suppress the expression of all the target genes independently and with high efficiency, acting via a Dicer-dependent mechanism. tsiRNA is diced into 42-and 21-bp duplexes inside the cell. tsiRNA-induced gene silencing is characterized by kinetics similar to that of canonical siRNA, while the silencing efficiency is significantly higher than that of canonical siRNA with the same sequence.
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Keywords: 2 0 -O-methyl modifications; Dicer-substrate RNAs; LMP2; LMP7; MDR1; siRNA Application of small-interfering RNA (siRNA) for therapeutic purposes has several limitations. The presence of mutations in the target gene, as well as the involvement of several genes in the development of disease, greatly reduces the therapeutic effect of RNA interference (RNAi) inducers. Simultaneous inhibition of several genes is an effective strategy that could solve these problems. However, increasing the total dose of RNAi inducers can cause amplification of side effects, especially when used in combination with transfection agents, providing immunostimulatory and toxic effects. Using siRNA conjugates solves some of the problems of this kind; however, when used in high concentrations, transport ligands can also cause side effects. Considering the above, the construction of inductors capable of suppressing the expression of several genes with the efficiency and selectivity of canonical siRNA can provide new opportunities for the therapeutic use of RNAi.
The first attempts to use long dsRNA in mammalian cells have been unsuccessful [1] . It has been shown that long dsRNAs induce an uncontrolled interferon (IFN) response leading to global changes in gene expression profile and subsequent cell death [2] [3] [4] . Later, it was found that RNA duplexes up to 30 bp more effectively suppress the expression of target genes in comparison with canonical siRNA and do not cause a pronounced IFN response in most cell lines studied [1] . Recent reports demonstrated that longer duplexes (25-30 bp in length) are processed by Dicer into 21-bp siRNAs and loaded into RNA-induced silencing complex (RISC) more efficiently than canonical siRNAs and provide better gene silencing [5] . It has been shown that the RNAi effector complex containing Dicer and accessory proteins interacts with an Argonaut protein (Ago) and actively loads the bottom strand of the siRNA into the RISC. Such a model implies increased affinity of Dicer and Dicer/TRBP for longer dsRNAs, as Dicer requires a minimum stem length of 27-30 bp for efficient cleavage [5] [6] [7] [8] . Moreover, it was recently demonstrated [9] that 25-to 27-bp dsiRNAs (Dicersubstrate small-interfering RNAs) can be directly loaded into Ago2 and show better efficacy than canonical 21-bp siRNAs.
It has previously been shown that introduction of chemical modifications (e.g., 2
0 -O-methyl) in the 2 0 position of the ribose of G and U nucleotides significantly reduces the immunostimulatory activity of siRNA in vitro and in vivo [10] , and introduction of a limited number of chemically modified nucleotides (< 10%) is sufficient to achieve such an effect. Effective inhibition of the immunostimulatory activity of dsiRNA containing a limited number of 2 0 -O-methyl (2 0 -OMe) analogs of U and G in various cell lines was demonstrated [11] . Modification patterns of 25-to 27-bp dsRNAs including alternating 2 0 -OMe residues that do not span the expected Dicer cut site were found to be compatible with intracellular processing [6, 12] .
Since chemical modifications can block the immune response, we supposed that theoretically nothing prevents the use of partly modified dsRNAs of any length. Previously, we used selectively modified RNA duplexes 21, 42, and 63 bp in length targeting MDR1 mRNA and examined their ability to silence expression of the target gene and the specificity of their action [13] . We showed that 42-and 63-bp siRNAs induced more effective RNAi at lower concentrations than classical 21-bp siRNA without nonspecific immune effects acting in a Dicer-independent mode [13] .
Here, we designed a multimeric 63-bp trimeric small interfering RNA (tsiRNA) which contains in one duplex the sequences of siRNAs targeting mRNAs of MDR1, LMP2, and LMP7 genes containing a limited number of 2 0 -OMe modifications in nuclease-sensitive sites. We show that such tsiRNA is able to suppress the expression of all three target genes independently and with high efficiency, acting via a Dicer-dependent mechanism. tsiRNA is diced into 42-and 21-bp duplexes in the cell and silences the expression of target genes significantly more efficiently than canonical siRNA with the corresponding monomer sequence.
Materials and methods
siRNA synthesis and duplex annealing 
Real-time reverse transcription PCR (RT-PCR)
Total RNA was extracted from the cells using the SDS/ phenol method [14] . Quantification of specific mRNAs by RT-PCR was done essentially as described in Refs [13, 15] . The amount of mRNA of each gene was normalized to the amount of GAPDH mRNA (human or mouse) used as an internal standard.
The following gene-specific primers were used in this study:
mGAPDH forward: , and 96 h, the culture medium was removed and the total RNA was extracted from the cells using a mirVana miRNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA). Northern blotting was performed as described by us previously [13] .
Results

Design of siRNAs
According to our recent data [13] , selectively modified 63-bp tsiMDR (previously referred to as siMDR-T in Ref. [13] ) effectively inhibits the expression of the MDR1 gene, but is not processed by Dicer in the cell. One possible reason for the lack of processing may be the presence of 2 0 -OMe modifications in the regions flanking Dicer cleavage sites. Potential sites of Dicer cleavage in siMDR-T are free from modifications, but the modifications are located at a distance of three nucleotides from them. Despite that the trimer siRNA is not cut into three monomer units, its biological activity is substantially higher than that of the monomeric siRNA, which can be attributed to more efficient assembly of RISC via a noncanonical mechanism. This is consistent with the differences in the inhibitory effect kinetics. The other explanation for increased activity Target 557-577 n MDR1 mRNA (NM_14758) siMDR
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could be more effective selection of the antisense strand as a guide in RISC. If processing of tsiRNA by Dicer is enabled, either improved kinetics and increased efficiency of inhibition through increasing the copy number of inhibitors, formed as a result of tsiRNA cleavage into 39 siRNA, or loss of efficiency from switching to another mechanism of action, can be expected. Therefore, the objective of this study was to compare the effectiveness of Dicer-dependent and Dicerindependent mechanisms of action of multimeric siRNA. To do this, we designed 63-bp trimers (tsiMDR-m-n-n) with a sequence similar to tsiMDR, in which all the original 2 0 -OMe modifications were present only in the first monomeric sequence, while in that part of the duplex which is cut off during processing by Dicer, the number of modifications was reduced and the layout was limited to the central regions, mainly of the sense strand (Table 1) . It is necessary to keep a limited number of modifications in each monomeric copy to prevent the development of the IFN response during partial processing of tsiRNA.
Small-interfering RNAs targeting multiple genes, or several different regions of one gene simultaneously, have great advantages in the treatment of complex diseases such as cancer and autoimmune diseases [16] . Therefore, the actual task is creation of multimeric inductors of RNAi targeted to several (in our case three) different genes (tsiCombi). We assumed that the expansion of regions free from modifications in the areas flanking the potential Dicer cleavage sites would lead to efficient processing, whereby long tsiCombi is cleaved into shorter 21-bp monomers wherein each monomer will suppress the expression of its specific target gene (Table 1 ). The sequences of siRNAs targeted at human MDR1 mRNA and at two mouse inducible immunoproteasome subunits LMP2 and LMP7 mRNAs, siMDR, siLMP2, and siLMP7, respectively, were selected by us previously [15, 17] and used in this work as the components of tsiCombi. Target mRNAs from different species were selected to validate the independent mode of action of the inhibitors. The appropriate monomers siMDR, siLMP2, and siLMP7 were used as positive controls of biological activity (Table 1) .
We investigated the stability of tsiCombi in the presence of 5% and 50% serum in order to determine whether the decrease in the number of 2 0 -OMe modifications compromised substantially the nuclease resistance of tsiRNA. The data show that the half-life of tsiCombi in the presence of 5% of the serum was 9.2 h and in the presence of 50% of the serum was 3.7 h (electrophoresis data and kinetics of degradation are given in the supplementary materials, Fig. S1 ).
Earlier we have shown that nonmodified siMDR was completely cleaved in the presence of 5% serum in < 15 min, while siMDR used in this study in which all nuclease-sensitive sites contain modifications is much more stable and remained stable up to 8 and 4 h in the presence of 5% and 50% serum, respectively [17] .
siRNA-mediated silencing of P-glycoprotein expression
We used NSO cells to determine the efficacy of LMP2 and LMP7 gene silencing, and MDR KB-8-5 cells overexpressing the MDR1 gene for the MDR1 gene silencing assay. The duration of the inhibitory effect of tsiRNA was measured by qRT-PCR over 48-120 h after transfection. In the first stage, we compared the efficacy and duration of the silencing effect of tsiRNAs containing one or three copies of an siRNA sequence directed to MDR1 mRNA: tsiCombi, tsiMDR-m-n-n, and tsiMDR (described in Ref. [13] ) on the MDR1 mRNA level in KB-8-5 cells (Fig. 1) .
tsiCombi and tsiMDR-m-n-n displayed similar silencing effect kinetics on MDR1 gene expression throughout 120 h after transfection. In contrast, tsiMDR demonstrated delayed development of silencing; however, its maximal efficiency was similar to the efficiency of both tsiCombi and tsiMDR-m-n-n ( Fig. 1) . At 48 h after transfection, the effectiveness of silencing by tsiCombi, as well as by tsiMDR-m-n-n, was 30-40%, whereas the efficiency of tsiMDR was negligible (about 10%). At 72 h post-transfection, the MDR1 gene expression level under the action of tsiCombi and tsiMDR-m-n-n decreased to 37-40% compared with the control. The level of MDR1 gene expression in cells transfected with tsiMDR was markedly higher (about 65%). At 96-120 h post-transfection of all three multimeric tsiRNAs, a similar inhibitory effect was demonstrated. The efficiency of tsiCombi, tsiMDR-m-n-n, and tsiMDR at these time points was maximal and reached 75-80% in comparison with the control.
The ability of tsiCombi to inhibit gene expression of inducible subunits of the immunoproteasome (LMP2 and LMP7) was examined in NSO cells. We showed that all the monomer components of tsiCombi are fully functional and have a similar inhibitory effect to canonical siRNA targeted at the same genes (Fig. 2) . It should be noted that tsiCombi and, correspondingly, each individual monomer within tsiCombi were used at a concentration three times lower (66.6 nM) than the corresponding canonical siRNA (200 nM). LMP2 gene expression began to decline under the action of tsiCombi 48 h after transfection to 30-35%, and reached a minimum level after 96 h (65-70% inhibition). At 120 h, only a slight increase in LMP2 mRNA level was observed (Fig. 2) . Significant (~75%) inhibition of LMP7 gene expression was achieved 48 h post-transfection of cells with tsiCombi, and this low level was maintained until 96 h. Similar to LMP2, the level of LMP7 mRNA started to increase slightly at 120 h post-transfection (Fig. 2) .
siRNA processing in the cells
We have previously shown that multimeric tsiMDR (labeled in a previous report as siMDR-T) comprising three copies of the monomer sequence effectively inhibits target gene expression; however, it is not processed by Dicer. Reducing the number of modified residues enabled us to obtain tsiRNAs in which each monomer was functional (tsiMDR-m-n-n and tsiCombi), as we have shown that this RNAi inductor exhibits similar silencing effect kinetics to canonical siRNA and each monomeric unit acts independently. This is only possible if the multimeric tsiRNAs are processed by Dicer into 21-bp siRNAs. To test this hypothesis and to clarify the mechanism of degradation of the target mRNA under the action of tsiMDR-m-n-n and tsiCombi, we analyzed tsiRNA processing in cells by northern blot analysis. For this purpose, siMDR, tsiMDR, tsiMDR-m-n-n, and tsiCombi were transfected into KB-8-5 cells; 48 and 72 h post-transfection, total RNA was isolated. Northern blot analysis showed that unlike tsiMDR, tsiMDRm-n-n and tsiCombi are cut by Dicer into the monomer or into a dimer and then into the monomer (Fig. 3) . Thus, these data confirm that 2 0 -OMe modifications adjacent to Dicer cleavage sites may adversely affect the efficiency of processing. Long multimeric tsiRNA (tsiCombi and tsiMDR-m-n-n) containing a limited number of modifications are processed effectively into short, fully functional monomers. As a result of tsiMDR-m-nn processing, dimers with a length of 42 bp are visible at the 48 h time point in the blot apart from the monomers, indicating incomplete cleavage of the trimer at the early time points. At the same time points for tsiCombi processing, dimers were not recorded, due to the specificity of the hybridization probe used, which was complementary to MDR1 mRNA. During processing within 72 h intact trimers were also detected in the cells, which may be related to an excess of our tsiRNA over the proteins involved in RNAi; as a result, some tsiRNA not involved in mRNA target cleavage could be preserved in compartments inaccessible for processing. The other possibility is the detention in nontarget compartments in the process of transfection.
Discussion
Comparison of the activity of tsiRNA with a limited number of modifications (tsiCombi and tsiMDR-m-n-n) acting in a Dicer-dependent mode with the activity of the previously studied selectively modified trimer (tsiMDR), which is not processed by Dicer, showed that Dicer-substrate tsiRNAs develop their silencing effect faster. The observed differences in the kinetics of inhibition may be associated with the processing of tsiCombi and tsiMDR-m-n-n into 21-bp siRNAs, whereby these siRNAs form RISCs by a Dicer/TRBP-mediated mechanism. Conversely, tsiMDR, as previously shown by northern blot analysis, is not processed by Dicer, and apparently it directly forms a complex with Ago2 via a noncanonical RNAi mechanism, since it does exhibit the silencing activity [18] . The latter assumption is supported by a study in which 38-bp siRNAs were not processed by Dicer, but had an inhibitory effect on the target genes acting according to the RNAi mechanism [19] . We hypothesized that the direct formation of RISC, bypassing processing by Dicer, requires more time, so the interfering activity of siRNA is manifested later. Comparison of tsiCombi with canonical siRNAs directed to inducible immunoproteasome subunits showed similar silencing kinetics of the corresponding genes, which indicates that processing is not a rate-limiting factor for RNAi. Moreover, the effectiveness of these tsiRNAs hardly differed from the effectiveness of free monomers although used at higher concentrations. Thus, it can be concluded that all the monomer components of the trimer are active and their association in a single duplex substantially increases the effectiveness of each monomer, and the desired biological effect can be achieved at much lower concentrations of RNAi inducer.
Using multimeric tsiRNAs designed to suppress the expression of multiple genes may be an effective treatment for many complex diseases. In our work, we have developed a combined inductor of RNAi 63 bp in length, capable of effectively suppressing expression of the three target genes -tsiCombi. To suppress unspecific IFN response, 2 0 -OMe modifications were introduced (Fig. S2) . Cleavage of long tsiRNAs into short monomers contributed to long-lasting and effective silencing of three different target genes for 120 h after transfection.
We have shown that tsiCombi with a reduced number of modifications, which allows it to be processed by Dicer, exhibits a fairly high stability in the presence of serum. Earlier we have shown that the presence of only two unprotected nuclease-sensitive sites in siMDR substantially decreased its nuclease resistance: its halflife time decreased to 30 min -1 h at the presence of 5% and 50% serum, respectively [17] . However, the lack of modifications in the central region of another siRNA targeted to 598-618 nt of MDR1 mRNA, which is distinguished by higher thermostability of the duplex, has less significant effect on its stability -it remains intact up to 4 h in 5% serum [17] . In the case of tsiRNA, the lack of modifications in a number of nuclease-sensitive sites also does not lead to a dramatic drop in its nuclease resistance, possibly due to the higher thermostability of the longer duplex. Our tsiRNA demonstrates a fairly high half-life in the presence of serum (3.7 and 9.2 h for 50% and 5% serum, respectively) to be used for delivery to cells in vitro and in vivo, since it is corresponding with the time required for transfection and exceeds the clearance time of typical nucleic acid preparations from the bloodstream. Northern blot data confirm that even after a few days post-transfection, intact tsiRNA and undamaged products of its processing are present in the cells.
Our tsiRNAs have higher specificity and lower toxicity than the other currently most widely used immunoproteasome selective inhibitors and therefore may be successfully used to generate new therapeutic agents in antitumor therapy. Furthermore, using the developed principles of tsiRNA design, one can create powerful inducers of RNAi to suppress the expression of any combination of target genes. 
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